ATE366809T1 - Addressine der schleimhaut und der blutgefässe und ihre verwendung - Google Patents

Addressine der schleimhaut und der blutgefässe und ihre verwendung

Info

Publication number
ATE366809T1
ATE366809T1 AT96906504T AT96906504T ATE366809T1 AT E366809 T1 ATE366809 T1 AT E366809T1 AT 96906504 T AT96906504 T AT 96906504T AT 96906504 T AT96906504 T AT 96906504T AT E366809 T1 ATE366809 T1 AT E366809T1
Authority
AT
Austria
Prior art keywords
madcam
primate
recombinant
proteins
relates
Prior art date
Application number
AT96906504T
Other languages
English (en)
Inventor
Michael J Briskin
Douglas J Ringler
Dominic Picarella
Walter Newman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27011628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/386,857 external-priority patent/US6551593B1/en
Priority claimed from US08/523,004 external-priority patent/US7750137B2/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE366809T1 publication Critical patent/ATE366809T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
AT96906504T 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung ATE366809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/386,857 US6551593B1 (en) 1995-02-10 1995-02-10 Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US08/523,004 US7750137B2 (en) 1995-09-01 1995-09-01 Mucosal vascular addressins

Publications (1)

Publication Number Publication Date
ATE366809T1 true ATE366809T1 (de) 2007-08-15

Family

ID=27011628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906504T ATE366809T1 (de) 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung

Country Status (12)

Country Link
EP (1) EP0808367B1 (de)
JP (1) JP4205162B2 (de)
AT (1) ATE366809T1 (de)
AU (1) AU4986296A (de)
CA (1) CA2212702C (de)
DE (1) DE69637155T2 (de)
DK (1) DK0808367T3 (de)
ES (1) ES2290955T3 (de)
MX (1) MX9706049A (de)
NZ (1) NZ303523A (de)
PT (1) PT808367E (de)
WO (1) WO1996024673A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503271A (ja) * 1996-11-01 2001-03-13 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド ヒト粘膜アドレシン細胞接着分子―1(MAdCAM―1)およびそのスプライス変異体
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
WO1999058573A1 (en) * 1998-05-13 1999-11-18 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AU2007201698B2 (en) * 1998-05-13 2011-10-13 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
WO2003047526A2 (en) * 2001-11-30 2003-06-12 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
RU2349598C2 (ru) 2003-05-01 2009-03-20 Дзе Скриппс Рисерч Инститьют Селективные антагонисты r-кадгерина и способы
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
HUE058817T2 (hu) * 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
ES2351057T3 (es) * 2005-07-08 2011-01-31 Pfizer Limited Anticuerpos contra madcam.
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA3017743A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017160700A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
US11760803B2 (en) 2016-03-24 2023-09-19 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
BR112019022268A2 (pt) 2017-04-28 2020-05-19 Millennium Pharmaceuticals, Inc. método para o tratamento de distúrbios pediátricos
CR20200076A (es) * 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
TW202110885A (zh) * 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向MAdCAM之免疫耐受性
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013312A1 (en) * 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression

Also Published As

Publication number Publication date
ES2290955T3 (es) 2008-02-16
NZ303523A (en) 2002-02-01
DK0808367T3 (da) 2007-11-05
AU4986296A (en) 1996-08-27
DE69637155D1 (de) 2007-08-23
CA2212702A1 (en) 1996-08-15
EP0808367A1 (de) 1997-11-26
JP4205162B2 (ja) 2009-01-07
CA2212702C (en) 2010-04-20
JPH10513365A (ja) 1998-12-22
MX9706049A (es) 1998-02-28
DE69637155T2 (de) 2008-02-07
EP0808367B1 (de) 2007-07-11
PT808367E (pt) 2007-10-22
WO1996024673A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
ATE366809T1 (de) Addressine der schleimhaut und der blutgefässe und ihre verwendung
Geiser et al. The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes
ES2063350T5 (es) Nuevas proteinas con efecto inhibidor del tnf y su obtencion.
CA2073045C (en) A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
KR101151805B1 (ko) 바이포달 펩타이드 바인더
US20060173162A1 (en) Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
JP2742925B2 (ja) 血栓形成抑制用治療薬組成物
Okamoto et al. Total chemical synthesis and biological activities of glycosylated and non‐glycosylated forms of the chemokines CCL1 and Ser‐CCL1
Kokot et al. Tamm-Horsfall protein updated
WO1996022371A3 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
KR970002917B1 (ko) 인터루킨-i 억제제
JPH03204896A (ja) インターフェロンレセプター細胞外断片
US5665346A (en) Human interleukin-8 analogs
KR100237936B1 (ko) 인터루킨-1 길항제
EA009414B1 (ru) Терапевтические применения вариантов хемокинов
Campistol et al. Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
KR0150000B1 (ko) 사람 macif 활성을 지닌 단백질을 암호화하는 유전자, 이 유전자를 함유하는 발현 벡터, 형질전환 세포 및 사람 macif 활성을 갖는 단백질
EP1683866B1 (de) Deletionsmutanten des IgE-abhängigen Histamin-Releasing-Faktor (HRF) mit der Fähigkeit zur Histaminfreisetzung, HRF-bindende Peptide sowie deren Verwendung
CN111848780A (zh) 一种IL-36的可溶性受体sIL-36R及其应用
EP0698666B1 (de) Modifiziertes Epimorphin
JP3103531B2 (ja) ヒト尿由来細胞接着糖蛋白質及びその製造方法
Deyl et al. Collagen αA and αB chains constitute two separate molecular species
EP0333517A2 (de) Methode und Mittel zur Hemmung der Bindung von menschlichen polymorphonuklearen Leukozyten an das Endothelium und sie enthaltende Zusammensetzungen